The place of ceftobiprole medocaril in the treatment of patients with community-acquired and nosocomial pneumonia
https://doi.org/10.18093/0869-0189-2026-36-4-728-737
Abstract
Ceftobiprole medocaril is a fifth-generation cephalosporin antibiotic with expanded activity against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus, and the activity against Gram-negative bacteria characteristic of third- and fourth-generation cephalosporins. The aim was to determine the role of ceftobiprole medocaril in the treatment of patients with community-acquired and nosocomial pneumonia in the context of increasing antibiotic resistance and post-infectious immune disorders based on an analysis of current literature and our own clinical experience. Results. The first clinical case demonstrates the efficacy of empirical ceftobiprole therapy in a hospitalized patient with community-acquired pneumonia and signs of lung tissue destruction, clinical predictors of challenging pathogens, and predictors of the ineffectiveness of initial antibacterial regimens in the prehospital setting. The second case demonstrates the successful use of the drug in a patient with severe neurological deficit requiring tracheostomy and gastrostomy, recurrent nosocomial lower respiratory tract infections associated with pan-resistant gram-negative bacteria, and exhaustion of various antibacterial treatment options. Ceftobiprole medocaril is included in our clinic’s internal empirical antibacterial therapy protocols for community-acquired and early nosocomial pneumonia, and extensive experience has been accumulated in this patient population. Conclusion. We recommend scaling up our experience in using ceftobiprole in patients with community-acquired pneumonia and the risk of challenging pathogens. The approach described in the second case study can be considered in complex clinical situations associated with exhaustion of antibacterial treatment options and requires further research.
About the Authors
V. P. Sereda
Limited Liability Company “My Medical Center High Technologies”; Federal State Budgetary Educational Institution of Higher Education “St. Petersburg State University”, Government of the Russian Federation; Federal State Budgetary Educational Institution of Higher Education “Pavlov First Saint Petersburg State Medical University”, Ministry of Healthcare of Russian Federation
Russian Federation
Competing Interests:
Russian Federation
Vitaly P. Sereda, Doctor of Medicine, Deputy Chief Physician for Therapy; Professor, Department of Hospital Therapy, Medical Institute; Leading Researcher, Research Institute of Interstitial and Orphan Lung Diseases, Scientific and Clinical Research Center; tel.: (812) 620-20-20; ext. 7700
Klinika Beloostrov territory, build. 1, housing 1, Yukkovskoye rural settlement, Leningrad Region, Vsevolozhskiy microdistrict,188632
Universitetskaya Naberezhnaya 7 – 9, Saint-Petersburg, 199034
ul. L’va Tolstogo 6 – 8, Saint-Petersburg, 197022
Competing Interests:
Sereda V.P. and Amelina A.A. declare receiving speaker honoraria from “Lancet” JSC for conference presentations. Shirinskaya A.V. declares no competing financial or non-financial interests. The authors confirm that “Lancet” JSC had no involvement in the study design, data analysis, manuscript preparation, or the publication decision.
A. A. Аmelina
Limited Liability Company “My Medical Center High Technologies”
Russian Federation
Competing Interests:
Russian Federation
Anna A. Amelina, Head of the Clinical Pharmacology Department; tel.: (812) 620-20-20; ext. 7700
Klinika Beloostrov territory, build. 1, housing 1, Yukkovskoye rural settlement, Leningrad Region, Vsevolozhskiy microdistrict,188632
Competing Interests:
Sereda V.P. and Amelina A.A. declare receiving speaker honoraria from “Lancet” JSC for conference presentations. Shirinskaya A.V. declares no competing financial or non-financial interests. The authors confirm that “Lancet” JSC had no involvement in the study design, data analysis, manuscript preparation, or the publication decision.
A. V. Shirinskia
Limited Liability Company “My Medical Center High Technologies”
Russian Federation
Competing Interests:
Russian Federation
Anna V. Shirinskaya, Clinical Pharmacologist; tel.: (812) 620-20-20; доб. 7700
Klinika Beloostrov territory, build. 1, housing 1, Yukkovskoye rural settlement, Leningrad Region, Vsevolozhskiy microdistrict,188632
Competing Interests:
Sereda V.P. and Amelina A.A. declare receiving speaker honoraria from “Lancet” JSC for conference presentations. Shirinskaya A.V. declares no competing financial or non-financial interests. The authors confirm that “Lancet” JSC had no involvement in the study design, data analysis, manuscript preparation, or the publication decision.
References
1. Aleksandrova G.A., Golubev N.A., Krasnova V.V. et al. [Healthcare in Russia 2025. Statistical collection]. Moscow: Rosstat; 2025. Available at: https://rosstat.gov.ru/storage/mediabank/Zdravooxran_2025.pdf (in Russian).
2. Titova O.N., Kuzubova N.A., Kozyrev A.G. et al. [Fatal outcomes analysis in pneumonia patients in St. Petersburg (2020–2024)]. Russkiy meditsinskiy zhurnal. 2025; (1): 7–12. DOI: 10.32364/2225-2282-2025-1-2 (in Russian).
3. Martínez Pérez-Crespo P.M., López Cortés L.E. Ceftobiprole: a clini cal view. Rev. Esp. Quimioter. 2021; 34 (Suppl. 1): 32–34. DOI: 10.37201/req/s01.09.2021.
4. Davies T.A., Page M.G.P., Shang W. et al. Binding of ceftobiprole and comparators to the penicillin-binding proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 2007; 51 (7): 2621–2624. DOI: 10.1128/AAC.00029-07.
5. Queenan A.M., Shang W., Kania M. et al. Interactions of ceftobiprole with β-lactamases from olecular Classes A to D. Antimicrob. Agents Chemother. 2007; 51 (9): 3089–3095. DOI: 10.1128/AAC.00218-07.
6. Moretó-Castellsagué C., González-Díaz A., Escrihuela-Vidal F. et al. In vitro activity of ceftobiprole plus ampicillin against Enterococcus faecalis causing infective endocarditis: phenotypic and genotypic characterization. J. Antimicrob. Chemother. 2025; 80 (9): 2513–2523. DOI: 10.1093/jac/dkaf260.
7. Horner C., Mushtaq S., Livermore D.M. et al. Activity of ceftaroline versus ceftobiprole against staphylococci and pneumococci in the UK and Ireland: analysis of BSAC surveillance data. J. Antimicrob. Chemother. 2020; 75 (11): 3239–3243. DOI: 10.1093/jac/dkaa306.
8. Arnés García D., Pitto-Robles I., Calderón Parra J. et al. Ceft-toceft study: real-life experience with ceftaroline and ceftobiprole in treatment of the principal infectious syndromes in a Spanish multicenter hospital cohort. Antibiotics. 2023; 12 (12): 1692. DOI: 10.3390/antibiotics12121692.
9. Hitt E.M., Bowers D.R. Ceftobiprole: a therapeutic update. Am. J. Health Syst. Pharm. 2025; 82 (11): e489–497. DOI: 10.1093/ajhp/zxaf006.
10. Sader H.S., Mendes R.E., Nicolau D.P. et al. Inference of ceftobiprole susceptibility through surrogate testing of ceftaroline. J. Clin.. 2026; 64 (4): e0170625. DOI: 10.1128/jcm.01706-25.
11. Ministry of Health of the Russian Federation [Clinical guidelines: Community-acquired pneumonia in adults]. Moscow; 2024. Available at: https://cr.minzdrav.gov.ru/preview-cr/654_2 (in Russian).
12. Shorr A.F., Jones M.E., Friedmann S. et al. Ceftobiprole versus ceftriaxone ± linezolid in community-acquired bacterial pneumonia (CABP): Re-analysis of a randomized, phase 3 study using 2020 FDA guidance. PLoS One. 2025; 20 (6): e0326758. DOI: 10.1371/journal.pone.0326758.
13. Scheeren T.W.L., Welte T., Saulay M. et al. Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials. BMC Infect. Dis. 2019; 19 (1): 195. DOI: 10.1186/s12879-019-3820-y.
14. Ceftobiprole in the treatment of patients with staphylococcus aureus bacteremia. ClinicalTrials.gov. NCT03138733. 2023. Available at: https://clinicaltrials.gov/study/NCT03138733 [Accessed: May 5, 2026].
15. Ceftobiprole in the treatment of patients with acute bacterial skin and skin structure Infections. ClinicalTrials.gov. NCT03137173. Available at: https://clinicaltrials.gov/study/NCT03137173 [Accessed: May 5, 2026].
16. Ceftobiprole in hospital acquired pneumonia. ClinicalTrials.gov. NCT00229008. Available at: https://clinicaltrials.gov/study/NCT00229008 [Accessed: May 5, 2026].
17. Awad S.S., Rodriguez A.H., Chuang Y.C. et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin. Infect. Dis. 2014; 59 (1): 51–61. DOI: 10.1093/cid/ciu219.
18. Hidalgo-Tenorio C., Pitto-Robles I., Arnés García D. et al. Cefto real-life study: real-world data on the use of ceftobiprole in a multicenter Spanish cohort. Antibiotics (Basel). 2023; 12 (7): 1218. DOI: 10.3390/antibiotics12071218.
19. Gentile I., Buonomo A.R., Corcione S. et al. CEFTO-CURE study: CEFTObiprole clinical use in real-lifE – a multi-centre experience in Italy. Int. J. Antimicrob. Agents. 2023; 62 (1): 106817. DOI: 10.1016/j.ijantimicag.2023.106817.
20. Lan S.H., Lee H.Z., Lai C.C. et al. Clinical efficacy and safety of ceftobiprole in the treatment of acute bacterial skin and skin structure infection: a systematic review and meta-analysis of randomized controlled trials. Expert Rev. Anti Infect. Ther. 2022; 20 (1): 95–102. DOI: 10.1080/14787210.2021.1927711.
21. Overcash J.S., Kim C., Keech R. et al. Ceftobiprole compared with vancomycin plus Aztreonam in the treatment of acute bacterial skin and skin structure infections: Results of a phase 3, randomized, double-blind trial (TARGET). Clin. Infect. Dis. 2021; 73 (7): e1507–1517. DOI: 10.1093/cid/ciaa974.
22. Hamed K., Engelhardt M., Jones M.E. et al. Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, phase III trial. Future Microbiol. 2020; 15 (1): 35–48. DOI: 10.2217/fmb-2019-0332.
23. Holland T.L., Cosgrove S.E., Doernberg S.B. et al. Ceftobiprole for treatment of complicated Staphylococcus aureus Bacteremia. N. Engl. J. Med. 2023; 389 (15): 1390–1401. DOI: 10.1056/NEJMoa2300220.
24. Corcione S., De Benedetto I., Carlin M. et al. Real-world experience of ceftobiprole for community- and hospital-acquired pneumonia from a stewardship perspective. Microorganisms. 2024; 12 (4): 725. DOI: 10.3390/microorganisms12040725.
25. Zu S., Wen M., Lin Y. et al. Biological properties and clinical applications of ceftobiprole: current status and perspective review. LabMed Discovery. 2025; 2 (3): 100088. DOI: 10.1016/j.lmd.2025.100088.
26. Rachina S.A., Fedina L.V., Stafeev A.N. et al. [Ceftobiprole medocaril: clinical and pharmacological characteristics and possibilities of clinical use]. Klinicheskaya mikrobiologiya i antimikrobnaya khimioterapiya. 2024; 26 (3): 302–310. DOI: 10.36488/cmac.2024.3.302-310 (in Russian).
27. Gomon Yu.M., Petrichenko A.S. [A systematic review with meta-analysis and indirect comparison of the results of studies evaluating the efficacy and safety of ceftobiprole and ceftaroline in adult patients in the treatment of infections of various localizations]. Real’naya klinicheskaya praktika: dannye i dokazatel’stva. 2025; 5 (2): 40–57. DOI: 10.37489/2782-3784-myrwd-073 (in Russian)
Review
For citations:
Sereda V.P., Аmelina A.A., Shirinskia A.V. The place of ceftobiprole medocaril in the treatment of patients with community-acquired and nosocomial pneumonia. PULMONOLOGIYA. 2026;36(4):728-737. (In Russ.) https://doi.org/10.18093/0869-0189-2026-36-4-728-737
Views:
21
JATS XML
Email this article 